• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Venetoclax with dose-adjusted EPOCH-R may be a promising combination therapy for aggressive B-cell lymphoma

byKathleen Lau
October 21, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer

Tags: aggressive b-cell lymphomab-cellB-cell lymphomaB-cell malignancybloodblood cancercancercyclophosphamideDiffuse large B-cell lymphoma (DLBCL)doxorubicinepoch-retoposidefebrile neutropeniahematologylymphomaoncologyprednisoneprimary mediastinal large b-cell lymphomarituximabvenetoclaxvincristine
Previous Post

Treatment of patent ductus arteriosus in very low birth weight infants varies between hospitals

Next Post

Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

RelatedReports

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

March 20, 2023
Proton radiotherapy may be effective for refractory pituitary adenomas
Chronic Disease

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

March 18, 2023
Nivolumab may be effective in platinum-resistant ovarian cancer
Gastroenterology

Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer

March 15, 2023
Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B

March 15, 2023
Next Post
Prescription of antibiotics for acute respiratory infections increasing

Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

#VisualAbstract: Fulvestrant-palbociclib and letrozole-palbociclib are equally effective for HR⁺ advanced breast cancer

#VisualAbstract: Dose-escalated concurrent chemoradiotherapy does not improve survival in locally advanced esophageal cancer

Top 10 TV Shows to Binge Watch During Lockdown

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Symptom and viral relapse more common in COVID-19 patients without antiviral treatment
  • The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns
  • Post-traumatic stress disorder and sleep disorders may exhibit a bi-directional relationship in U.S military members
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options